US20190144458A1 - Ethynyl derivatives - Google Patents

Ethynyl derivatives Download PDF

Info

Publication number
US20190144458A1
US20190144458A1 US16/250,278 US201916250278A US2019144458A1 US 20190144458 A1 US20190144458 A1 US 20190144458A1 US 201916250278 A US201916250278 A US 201916250278A US 2019144458 A1 US2019144458 A1 US 2019144458A1
Authority
US
United States
Prior art keywords
compound
methyl
formula
dihydro
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/250,278
Other languages
English (en)
Inventor
Barbara Biemans
Georg Jaeschke
Antonio Ricci
Daniel Rueher
Fionn O'Hara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoffmann La Roche Inc
Original Assignee
Hoffmann La Roche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche Inc filed Critical Hoffmann La Roche Inc
Assigned to HOFFMANN-LA ROCHE INC. reassignment HOFFMANN-LA ROCHE INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: F. HOFFMANN-LA ROCHE AG
Assigned to F. HOFFMANN-LA ROCHE AG reassignment F. HOFFMANN-LA ROCHE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIEMANS, Barbara, JAESCHKE, GEORG, O'HARA, FIONN, RICCI, ANTONIO, RUEHER, DANIEL
Publication of US20190144458A1 publication Critical patent/US20190144458A1/en
Priority to US16/865,233 priority Critical patent/US11242349B2/en
Priority to US17/568,530 priority patent/US20220127275A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Definitions

  • the present invention relates to compounds of formulas IA and IB
  • the compounds of formulas IA and IB are positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4).
  • PAMs positive allosteric modulators
  • Metabotropic glutamate receptor 4 is a protein that in humans is encoded by the GRM4 gene.
  • GRM6 GRM7 and GRM8 it belongs to group III of the Metabotropic glutamate receptor family, and is negatively coupled to adenylate cyclase via activation of the G ⁇ i/o protein. It is expressed primarily on presynaptic terminals, functioning as an autoreceptor or heteroceptor and its activation leads to decreases in transmitter release from presynaptic terminals.
  • mGluR4 is currently receiving much attention based primarily upon its unique distribution and the recent evidence that activation of this receptor plays key modulatory role in many CNS and non-CNS pathways (Celanire S, Campo B, Expert Opinion in Drug Discovery, 2012)
  • mGluR4 PAMs are emerging as promising therapeutic agents for the treatment of motor (and non-motor) symptoms as well as a disease-modifying agent in Parkinson's disease through a non-dopaminergic approach.
  • Parkinson's disease is a progressive neurodegenerative disease that results in the loss of dopaminergic neurons in the substantia nigra (SN).
  • SN substantia nigra
  • One consequence of the depletion of dopamine in this disease is a series of movement disorders, including bradykinesia, akinesia, tremor, gait disorders and problems with balance. These motor disturbances form the hallmark of PD, although there are many other non-motor symptoms that are associated with the disease.
  • PD symptoms are effectively treated by dopamine replacement or augmentation, with the use of dopamine D2 receptor agonists, levodopa or monoamine oxidase B inhibitors. However, as the disease progresses these agents become less effective in controlling motor symptoms. Additionally, their use is limited by the emergence of adverse effects including dopamine agonist-induced dyskinesias.
  • mGluR4 metabotropic glutamate receptor 4
  • group III mGluRs A member of the group III mGluRs, mGluR4 is predominantly a presynaptic glutamate receptor that is expressed in several key locations in the basal ganglia circuits that control movement.
  • Activation of mGluR4 with group III-preferring agonists decreases inhibitory and excitatory post synaptic potentials, presumably by decreasing the release of GABA and glutamate respectively.
  • Orthosteric mGluR4 agonist L-AP4 has demonstrated neuroprotective effects in a 6-OHDA rodent model of PD and first positive allosteric modulator ( ⁇ )-PHCCC reduced nigrostriatal degeneration in mice treated with 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP).
  • MPTP 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine
  • Anxiety disorders are among the most prevalent psychiatric disorders in the world, and are co-morbid with Parkinson's disease (Prediger R, et al. Neuropharmacology 2012; 62:115-24). Excessive glutamatergic neurotransmission is one important feature of anxiety pathophysiology. Based on presynaptic localization of mGluR4 in brain areas involved in anxiety and mood disorders, and dampening excessive brain excitability, the mGluR4 activators may represent a new generation of anxiolytic therapeutics ( Eur. J. Pharmacol., 498(1-3), 153-6, 2004).
  • ADX88178 was active in two preclinical rodent models of anxiety: the marble burying test in mice and EPM in mice and rats. ADX88178 also displayed an anxiolytic-like profile in the rat EPM test after oral dosing.
  • mGluR4 modulators were also shown to exert anti-depressive actions ( Neuropharmacology, 46(2), 151-9, 2004).
  • mGluR4 modulators were also shown to be involved in glucagon secretion inhibition ( Diabetes, 53(4), 998-1006, 2004). Therefore, orthosteric or positive allosteric modulators of mGluR4 have potential for the treatment of type 2 diabetes through its hypoglycemic effect.
  • mGluR4 was shown to be expressed in prostate cancer cell-line ( Anticancer Res. 29(1), 371-7, 2009) or colorectal carcinoma ( Cli. Cancer Research, 11(9)3288-95, 2005). mGluR4 modulators may therefore have also potential role for the treatment of cancers.
  • Compounds of formulas IA and IB are distinguished by having valuable therapeutic properties. They can be used in the treatment or prevention of disorders, relating to allosteric modulators for the mGluR4 receptor.
  • the most preferred indications for compounds which are allosteric modulators for the mGluR4 receptor are Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, anorexia, autism, neuroprotection, cancer, depression and type 2 diabetes.
  • the present invention relates to compounds of formulas IA and IB and to their pharmaceutically acceptable salts, to these compounds as pharmaceutically active substances, to the processes for their production as well as to their use in the treatment or prevention of disorders, relating to allosteric modulators for the mGluR4 receptor, such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2 and to pharmaceutical compositions containing the compounds of formula IA and IB.
  • allosteric modulators for the mGluR4 receptor such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2 and to pharmaceutical compositions containing the compounds of formula IA and IB.
  • a further object of the present invention is a method for the treatment or prophylaxis of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, anorexia, autism, neuroprotection, cancer, depression and type 2 diabetes, which method comprises administering an effective amount of a compound of formulas IA and IB to a mammal in need.
  • the invention includes all racemic mixtures, all their corresponding enantiomers and/or optical isomers, or analogues containing isotopes of hydrogen, fluorine, carbon, oxygen or nitrogen.
  • pharmaceutically acceptable acid addition salt embraces a salt with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid or p-toluenesulfonic acid.
  • the compounds of formulas IA and IB can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art.
  • the reaction sequence is not limited to the one displayed in the schemes, however, depending on the starting materials and their respective reactivity the sequence of reaction steps can be freely altered. Starting materials are either commercially available or can be prepared by methods analogous to the methods given below, by methods described in references cited in the description or in the examples, or by methods known in the art.
  • a monoclonal HEK-293 cell line stably transfected with a cDNA encoding for the human mGlu4 receptor was generated; for the work with mGlu4 Positive Allosteric Modulators (PAMs), a cell line with low receptor expression levels and low constitutive receptor activity was selected to allow the differentiation of agonistic versus PAM activity.
  • PAMs mGlu4 Positive Allosteric Modulators
  • Cells were cultured according to standard protocols (Freshney, 2000) in Dulbecco's Modified Eagle Medium with high glucose supplemented with 1 mM glutamine, 10% (vol/vol) heat-inactivated bovine calf serum, Penicillin/Streptomycin, 50 ⁇ g/ml hygromycin and 15 ⁇ g/ml blasticidin (all cell culture reagents and antibiotics from Invitrogen, Basel, Switzerland).
  • L-AP4 (2S)-2-amino-4-phosphonobutanoic acid
  • FIG. 1 Illustration of the experimental outline for mGlu4 PAM Ca2+ mobilization screening assay and the determination of EC 50 and % Emax values.
  • the compounds of formulas IA and IB and pharmaceutically acceptable salts thereof can be used as medicaments, e.g. in the form of pharmaceutical preparations.
  • the pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions.
  • the administration can also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
  • the compounds of formulas IA and IB and pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations.
  • Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatin capsules.
  • Suitable carriers for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatin capsules.
  • Suitable carriers for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like.
  • Adjuvants such as alcohols, polyols, glycerol, vegetable oils and the like, can be used for aqueous injection solutions of water-soluble salts of compounds of formula IA and IB, but as a rule are not necessary.
  • Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
  • the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • medicaments containing a compound of formulas IA and IB or pharmaceutically acceptable salts thereof and a therapeutically inert excipient are also an object of the present invention, as is a process for the production of such medicaments which comprises bringing one or more compounds of formula IA and IB or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical dosage form together with one or more therapeutically inert carriers.
  • the dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case.
  • the effective dosage for oral or parenteral administration is between 0.01-20 mg/kg/day, with a dosage of 0.1-10 mg/kg/day being preferred for all of the indications described.
  • mg/capsule ingredient 5 25 100 500 Compound of formula IA or IB 5 25 100 500 Hydrous Lactose 159 123 148 — Corn Starch 25 35 40 70 Talk 10 15 10 25 Magnesium Stearate 1 2 2 5 Total 200 200 300 600
  • a compound of formula IA or IB, lactose and corn starch are firstly mixed in a mixer and then in a comminuting machine.
  • the mixture is returned to the mixer; the talc is added thereto and mixed thoroughly.
  • the mixture is filled by machine into suitable capsules, e.g. hard gelatin capsules.
  • a compound of formula IA or IB is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part). The pH is adjusted to 5.0 by acetic acid. The volume is adjusted to 1.0 ml by addition of the residual amount of water. The solution is filtered, filled into vials using an appropriate overage and sterilized.
  • Step 2 (NE)-2-Methyl-N-[1-(2-trimethylsilylethoxymethyl)-6,7-dihydro-5H-indazol-4-ylidene]propane-2-sulfinamide
  • Step 3 Methyl 2-[(4S)-4-[[(R)-tert-butylsulfinyl]amino]-1-(2-trimethylsilylethoxymethyl)-6,7-dihydro-5H-indazol-4-yl]acetate
  • Methyl acetate (22.25 g, 23.9 ml, 300.3 mmol, 3 equiv.) was dissolved in 370 ml of dry THF and the solution was cooled to ⁇ 70° C.
  • LDA 2.0 M in THF/heptane/ethylbenzene
  • 150 ml, 300.3 mmol, 3 equiv. was added drop wise at ⁇ 75° C. to ⁇ 65° C. and the mixture was stirred for 45 minutes at ⁇ 70° C.
  • Chlorotitanium triisopropoxide (1.0 M in dichloromethane) (400 ml, 400 mmol, 4 equiv.) was added drop wise at ⁇ 75° C.
  • Step 4 Methyl 2-[(4S)-4-amino-1-(2-trimethylsilylethoxymethyl)-6,7-dihydro-5H-indazol-4-yl]acetate
  • Step 5 Methyl 2-[(4S)-4-[(2,6-difluoro-4-iodo-phenyl)carbamoylamino]-1-(2-trimethylsilylethoxymethyl)-6,7-dihydro-5H-indazol-4-yl]acetate
  • Step 6 (4S)-3′-(2,6-Difluoro-4-iodo-phenyl)-1-(2-trimethylsilylethoxymethyl)spiro[6,7-dihydro-5H-indazole-4,6′-hexahydropyrimidine]-2′,4′-dione
  • Step 7 (4 S)-3′-(2,6-Difluoro-4-iodo-phenyl)-1′-methyl-1-(2-trimethylsilylethoxymethyl)spiro[6,7-dihydro-5H-indazole-4,6′-hexahydropyrimidine]-2′,4′-dione
  • the reaction mixture was poured into water and extracted three times with ethyl acetate. The organic layers were washed with water and brine, dried over sodium sulfate and evaporated to dryness.
  • the crude product was purified by flash chromatography on a silica gel column eluting with an petroleum:ethyl acetate 10:1 to 1:1 gradient.
  • Step 8 (4S)-3′-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-1′-methyl-1-(2-trimethylsilylethoxymethyl)spiro[6,7-dihydro-5H-indazole-4,6′-hexahydropyrimidine]-2′,4′-dione
  • Triethylamine (10.1 g, 13.9 ml, 99.6 mmol, 5 equiv.), bis-(triphenylphosphine)-palladium(II)dichloride (420 mg, 0.6 mmol, 0.03 equiv.), triphenylphosphine (313 mg, 1.2 mmol, 0.06 equiv.) and copper(I)iodide (114 mg, 0.6 mmol, 0.03 equiv.) were added and the mixture was stirred for 3 hours at 60° C. The reaction mixture was evaporated with Isolute®.
  • Step 9 (4S)-3′-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-1′-methyl-spiro[1,5,6,7-tetrahydroindazole-4,6′-hexahydropyrimidine]-2′,4′-dione
  • Step 10 (4S)-3′-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-2-ethyl-1′-methyl-spiro[6,7-dihydro-5H-indazole-4,6′-hexahydropyrimidine]-2′,4′-dione

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
US16/250,278 2016-07-18 2019-01-17 Ethynyl derivatives Abandoned US20190144458A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/865,233 US11242349B2 (en) 2016-07-18 2020-05-01 Ethynyl derivatives
US17/568,530 US20220127275A1 (en) 2016-07-18 2022-01-04 Ethynyl derivatives

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16179837.6 2016-07-18
EP16179837 2016-07-18
PCT/EP2017/067495 WO2018015235A1 (en) 2016-07-18 2017-07-12 Ethynyl derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/067495 Continuation WO2018015235A1 (en) 2016-07-18 2017-07-12 Ethynyl derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/865,233 Continuation US11242349B2 (en) 2016-07-18 2020-05-01 Ethynyl derivatives

Publications (1)

Publication Number Publication Date
US20190144458A1 true US20190144458A1 (en) 2019-05-16

Family

ID=56418435

Family Applications (3)

Application Number Title Priority Date Filing Date
US16/250,278 Abandoned US20190144458A1 (en) 2016-07-18 2019-01-17 Ethynyl derivatives
US16/865,233 Active US11242349B2 (en) 2016-07-18 2020-05-01 Ethynyl derivatives
US17/568,530 Pending US20220127275A1 (en) 2016-07-18 2022-01-04 Ethynyl derivatives

Family Applications After (2)

Application Number Title Priority Date Filing Date
US16/865,233 Active US11242349B2 (en) 2016-07-18 2020-05-01 Ethynyl derivatives
US17/568,530 Pending US20220127275A1 (en) 2016-07-18 2022-01-04 Ethynyl derivatives

Country Status (31)

Country Link
US (3) US20190144458A1 (es)
EP (1) EP3484889B1 (es)
JP (1) JP6936305B2 (es)
KR (1) KR20190026805A (es)
CN (1) CN109476671B (es)
AR (1) AR109075A1 (es)
AU (1) AU2017299083B2 (es)
BR (1) BR112019000314A2 (es)
CA (1) CA3030788A1 (es)
CL (1) CL2019000045A1 (es)
CO (1) CO2018013824A2 (es)
CR (1) CR20190014A (es)
DK (1) DK3484889T3 (es)
ES (1) ES2826389T3 (es)
HR (1) HRP20201615T1 (es)
HU (1) HUE051006T2 (es)
IL (1) IL263884A (es)
LT (1) LT3484889T (es)
MA (1) MA45665B1 (es)
MX (1) MX2019000442A (es)
PE (1) PE20190382A1 (es)
PH (1) PH12019500119A1 (es)
PL (1) PL3484889T3 (es)
PT (1) PT3484889T (es)
RS (1) RS60908B1 (es)
RU (1) RU2745068C2 (es)
SG (1) SG11201811829QA (es)
SI (1) SI3484889T1 (es)
TW (1) TWI729169B (es)
WO (1) WO2018015235A1 (es)
ZA (1) ZA201900113B (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11034699B2 (en) 2015-07-15 2021-06-15 Hoffmann-La Roche Inc. Ethynyl derivatives
US12006323B2 (en) 2015-07-15 2024-06-11 Hoffmann-La Roche Inc. Ethynyl derivatives

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110183456A (zh) * 2019-07-11 2019-08-30 河南师范大学 一种2-芳基吲唑琥珀酰亚胺螺环化合物的合成方法
US11515154B2 (en) * 2020-10-27 2022-11-29 Applied Materials, Inc. Selective deposition of a passivation film

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10189848B2 (en) * 2015-07-15 2019-01-29 Hoffmann-La Roche Inc. Ethynyl derivatives

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050039A2 (en) * 2002-12-04 2004-06-17 Merck & Co., Inc. Spirocyclic ureas, compositions containing such compounds and methods of use
RU2478639C2 (ru) 2005-05-24 2013-04-10 Лаборатуар Сероно С.А. Трициклические спиро-производные в качестве модуляторов crth2
WO2008027466A1 (en) 2006-08-31 2008-03-06 Schering Corporation Hydantoin derivatives useful as antibacterial agents
NZ581817A (en) 2007-06-03 2012-05-25 Univ Vanderbilt Benzamide mglur5 positive allosteric modulators and methods of making and using same
CA2773038A1 (en) 2009-09-04 2011-03-10 P. Jeffrey Conn Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
US8759377B2 (en) 2009-11-23 2014-06-24 Vanderbilt University Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
US8772300B2 (en) 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives
KR101554803B1 (ko) 2011-04-26 2015-09-21 에프. 호프만-라 로슈 아게 Mglur5의 양성 알로스테릭 조절체로서 에틴일 유도체
US10533000B2 (en) 2011-05-26 2020-01-14 Sunovion Pharmaceuticals, Inc. Metabotrophic glutamate receptor 5 modulators and methods of use thereof
PT2729448E (pt) * 2011-07-06 2015-12-02 Gilead Sciences Inc Compostos para o tratamento de vih
US20130123254A1 (en) 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
UA110862C2 (uk) 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
CA2879489A1 (en) 2012-10-18 2014-04-24 F.Hoffmann-La Roche Ag Ethynyl derivatives as modulators of mglur5 receptor activity
KR101656634B1 (ko) 2012-10-18 2016-09-09 에프. 호프만-라 로슈 아게 mGluR5 수용체 활성의 조절제로서 에틴일 유도체
WO2014124560A1 (en) 2013-02-18 2014-08-21 Hua Medicine (Shanghai) Ltd. Mglur regulators
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
MA38885B1 (fr) * 2013-09-25 2018-11-30 Hoffmann La Roche Dérivés d'éthynyle modulateurs allosteriques positifs (pam) du recepteur metabotropique du glutamate 4 (mglu4)
TWI649310B (zh) 2014-01-10 2019-02-01 赫孚孟拉羅股份公司 乙炔基衍生物
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
PL3110802T3 (pl) * 2014-02-25 2019-03-29 F. Hoffmann-La Roche Ag Pochodne etynylowe
JP6539749B2 (ja) 2015-03-19 2019-07-03 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ｍＧｌｕＲ４のモジュレーターとしての３−（４−エチニルフェニル）ヘキサヒドロピリミジン−２，４−ジオン誘導体
US10391998B2 (en) 2016-11-16 2019-08-27 Ford Global Technologies, Llc Vehicle systems and methods for reducing electrified vehicle noise, vibration, and harshness

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10189848B2 (en) * 2015-07-15 2019-01-29 Hoffmann-La Roche Inc. Ethynyl derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11034699B2 (en) 2015-07-15 2021-06-15 Hoffmann-La Roche Inc. Ethynyl derivatives
US12006323B2 (en) 2015-07-15 2024-06-11 Hoffmann-La Roche Inc. Ethynyl derivatives

Also Published As

Publication number Publication date
CO2018013824A2 (es) 2018-12-28
EP3484889B1 (en) 2020-08-19
AU2017299083B2 (en) 2021-06-24
AR109075A1 (es) 2018-10-24
SI3484889T1 (sl) 2020-11-30
RS60908B1 (sr) 2020-11-30
PH12019500119A1 (en) 2019-12-11
CR20190014A (es) 2019-03-04
AU2017299083A1 (en) 2019-01-24
EP3484889A1 (en) 2019-05-22
JP6936305B2 (ja) 2021-09-15
CL2019000045A1 (es) 2019-06-07
MA45665B1 (fr) 2020-11-30
LT3484889T (lt) 2020-11-10
SG11201811829QA (en) 2019-02-27
RU2019102757A3 (es) 2020-08-18
HUE051006T2 (hu) 2021-01-28
US20200255440A1 (en) 2020-08-13
MX2019000442A (es) 2019-06-20
WO2018015235A1 (en) 2018-01-25
RU2745068C2 (ru) 2021-03-18
US11242349B2 (en) 2022-02-08
DK3484889T3 (da) 2020-10-26
JP2019521158A (ja) 2019-07-25
PT3484889T (pt) 2020-10-15
HRP20201615T1 (hr) 2020-12-11
ES2826389T3 (es) 2021-05-18
KR20190026805A (ko) 2019-03-13
TWI729169B (zh) 2021-06-01
BR112019000314A2 (pt) 2019-04-16
TW201805287A (zh) 2018-02-16
US20220127275A1 (en) 2022-04-28
ZA201900113B (en) 2019-09-25
RU2019102757A (ru) 2020-08-18
PE20190382A1 (es) 2019-03-08
CN109476671B (zh) 2021-09-24
CA3030788A1 (en) 2018-01-25
PL3484889T3 (pl) 2020-12-28
CN109476671A (zh) 2019-03-15
IL263884A (en) 2019-01-31

Similar Documents

Publication Publication Date Title
US11034699B2 (en) Ethynyl derivatives
US20220127275A1 (en) Ethynyl derivatives
EP3092219B1 (en) Ethynyl-imidazolin-2,4-dione derivatives as mglur4 modulators
AU2015205661A1 (en) Ethynyl-imidazolin-2,4-dione derivatives as mGluR4 modulators
US10065956B2 (en) Ethynyl derivatives
US12006323B2 (en) Ethynyl derivatives
BR112017023084B1 (pt) Derivados de etinila como moduladores de receptor de glutamato metabotrópico, seu uso, seu processo de preparação e composição farmacêutica

Legal Events

Date Code Title Description
AS Assignment

Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:F. HOFFMANN-LA ROCHE AG;REEL/FRAME:048369/0902

Effective date: 20160829

Owner name: F. HOFFMANN-LA ROCHE AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BIEMANS, BARBARA;JAESCHKE, GEORG;RICCI, ANTONIO;AND OTHERS;REEL/FRAME:048371/0540

Effective date: 20160720

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION